報價延遲最少15分鐘:2024/05/04 11:13 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.15 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.49/-0.80
|
|
企業價值
757.32M
|
| 資產負債 |
|
每股賬面淨值
2.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
84.82M
|
|
每股收益
1.94
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/04 11:13 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. |